Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Pegvisomant

Pegvisomant

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 15 September 2026

Pegvisomant (Somavert) is a real, FDA-approved growth hormone receptor antagonist for acromegaly — mechanistically the opposite of the somatostatin analogs covered elsewhere on this site, blocking GH action directly at the receptor rather than suppressing GH secretion upstream.

On this page
  1. A GH receptor blocker, not a secretion suppressor
  2. The approval and pivotal trial
  3. Why biochemical success still requires imaging
  4. Current status

In brief

Should you care? Relevant if you're comparing acromegaly treatment mechanisms — this is the one drug in that space that works completely differently from the others.

The short version

  • A modified GH molecule itself — engineered to bind the GH receptor without activating it, blocking GH action directly.
  • Pivotal trial: IGF-1 normalized in 89% of patients at the highest dose, versus 10% on placebo.
  • A genuine monitoring quirk: because it works downstream of GH secretion, biochemical normalization doesn't rule out a still-growing pituitary tumor — imaging surveillance stays necessary regardless.

A GH receptor blocker, not a secretion suppressor

Pegvisomant is a genetically engineered growth hormone receptor antagonist — structurally, it's a modified human GH molecule itself (nine amino acid substitutions, plus PEGylation) that binds the GH receptor but fails to trigger the conformational change needed for receptor activation, while the PEG chains additionally block receptor dimerization. This is mechanistically distinct from the somatostatin analogs on this site (octreotide, lanreotide, pasireotide), which suppress GH secretion from the pituitary upstream. Pegvisomant instead blocks GH's action entirely downstream, at the receptor — which means endogenous GH levels actually rise on treatment, so GH itself can't be used to monitor response; IGF-1 is used instead.

The approval and pivotal trial

The FDA approved pegvisomant (as Somavert) on 26 March 2003, developed by Pharmacia Corporation (acquired by Pfizer later that year), for acromegaly in patients with an inadequate response to surgery/radiation or for whom those aren't appropriate. The pivotal trial (Trainer et al., N Engl J Med 2000, DOI: 10.1056/NEJM200004203421604) was a 12-week, randomized, placebo-controlled, dose-finding trial (112 patients): IGF-1 normalized in 10% of the placebo group versus 54%, 81%, and 89% of patients on 10mg, 15mg, and 20mg daily doses respectively. A separate long-term follow-up (van der Lely et al., Lancet 2001) reported that 97% of patients treated for a year or more achieved normal IGF-1 — though a large real-world registry (ACROSTUDY) found lower normalization rates in routine practice (roughly 54% at year one, climbing over long-term follow-up), a reminder that pivotal-trial results and everyday clinical practice don't always match.

Why biochemical success still requires imaging

Because pegvisomant blocks the GH receptor peripherally rather than acting on the pituitary tumor itself, it has no direct antiproliferative effect on the underlying adenoma. IGF-1 — the marker used to judge treatment success — can normalize even while a tumor continues to grow, meaning biochemical control can mask tumor progression that would otherwise be flagged. Periodic pituitary MRI is still required regardless of how well IGF-1 responds. The label also requires routine liver enzyme monitoring, with discontinuation if signs of hepatic injury appear.

Current status

Still marketed by Pfizer; no generic identified. We found no clear evidence of pegvisomant being sold on bodybuilding-adjacent grey-market sites, consistent with the biology — it blocks GH action, the opposite of what someone chasing GH/IGF-1 effects would want — and its complexity as an engineered, PEGylated protein makes it a poor fit for cheap grey-market manufacture.

References

  1. Trainer PJ, Drake WM, Katznelson L, et al., "Treatment of Acromegaly with the Growth Hormone-Receptor Antagonist Pegvisomant," N Engl J Med 2000;342(16):1171-1177, DOI: 10.1056/NEJM200004203421604.
  2. van der Lely AJ, Hutson RK, Trainer PJ, et al., "Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist," Lancet 2001;358(9295):1754-1759.
  3. FDA approval history for Somavert (pegvisomant), 26 March 2003.